J. B. Posner and N. L. Chernik, Intracranial metastases from systemic cancer, Adv Neurol, vol.19, pp.579-92, 1978.

J. D. Johnson and B. Young, Demographics of brain metastasis, Neurosurg Clin N Am, vol.7, pp.337-381, 1996.

A. K. Percy, L. R. Elveback, H. Okazaki, and L. T. Kurland, Neoplasms of the central nervous system. Epidemiologic considerations, Neurology, vol.22, pp.40-48, 1972.

A. E. Walker, M. Robins, and F. D. Weinfeld, Epidemiology of brain tumors: the national survey of intracranial neoplasms, Neurology, vol.35, pp.219-245, 1985.

L. Nayak, E. Q. Lee, and P. Y. Wen, Epidemiology of brain metastases, Curr Oncol Rep, vol.14, issue.1, pp.48-54, 2012.

J. Ferlay, M. Colombet, and M. Piñeros, Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, Int. J. Cancer

P. K. Brastianos, Clinical discussion and review of the management of brain metastases, J. Natl. Compr. Canc. Netw, vol.11, pp.1153-1164, 2013.

M. Kocher, R. Soffietti, and U. Abacioglu, Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study, J Clin Oncol, vol.29, pp.134-141, 2011.

R. A. Patchell, P. A. Tibbs, and W. F. Regine, Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial, JAMA, vol.280, pp.1485-1489, 1998.

H. Aoyama, H. Shirato, and M. Tago, Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial, JAMA, vol.295, pp.2483-2491, 2006.

E. M. Noordijk, C. J. Vecht, and H. Haaxma-reiche, The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age, Int J Radiat Oncol Biol Phys, vol.29, pp.711-717, 1994.

M. Brian, P. D. Alexander, . Brown, S. Manmeet, H. Ahluwalia et al., Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group, 2018.

K. J. Klos, O. Neill, and B. P. , Brain metastases. Neurologist, vol.10, pp.31-46, 2004.

E. A. Neuwelt, B. Bauer, and C. Fahlke, Engaging neuroscience to advance translational research in brain barrier biology, Nat Rev Neurosci, vol.12, pp.169-182, 2011.

M. Preusser, D. Capper, A. Ilhan-mutlu, A. S. Berghoff, P. Birner et al., Brain metastases: pathobiology and emerging targeted therapies, Acta Neuropathol, vol.123, issue.2, pp.205-222, 2012.

A. Louveau, Structural and functional features of central nervous system lymphatic vessels, Nature, vol.523, pp.337-341, 2015.

S. Patan, Tie1 and Tie2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth, Microvasc Res, vol.56, pp.1-21, 1998.

S. Yano, H. Shinohara, and R. S. Herbst, Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis, Cancer Res, vol.60, pp.4959-4967, 2000.

S. J. Kim, J. S. Kim, and E. S. Park, Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy, Neoplasia, vol.13, pp.286-298, 2011.

K. Felgenhauer, The blood-brain barrier redefined, J Neurol, vol.233, pp.193-194, 1986.

S. Genka, J. Deutsch, and P. L. Stahle, Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoamide mustard in the rat, Cancer Chemother Pharmacol, vol.27, pp.1-7, 1990.

A. Juloori, T. Samuel, and . Chao, Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases, J Neurosurg, vol.18, pp.1-9, 2019.

N. Rioux-leclercq, Hétérogénéité et progression tumorale, Bulletin AIP, vol.66, pp.49-53, 2017.

S. Dawood, K. Broglio, and F. J. Esteva, Survival among women with triple receptor-negative breast cancer and brain metastases, Ann Oncol, vol.20, pp.621-628, 2009.

L. Albiges, F. Andre, and C. Balleyguier, Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases, AnnOncol, vol.16, pp.1846-1853, 2005.

, INCa -Tumorothèques -Indications et recommandations -Actualisation, 2011.

D. Forman, F. Bray, D. H. Brewster, G. Mbalawa, C. Kohler et al., Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System, Cancer Incidence in Five Continents, vol.22, pp.2865-2872, 2004.

L. J. Schouten, J. Rutten, H. A. Huveneers, and A. Twijnstra, Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma, Cancer, vol.94, pp.2698-2705, 2002.

M. Valiente, M. S. Ahluwalia, and R. Soffietti, The Evolving Landscape of Brain Metastasis, Trends in Cancer, vol.4, issue.3, pp.176-196, 2018.

I. J. Fidler, The role of the organ microenvironment in brain metastasis, Semin Cancer Biol, vol.21, pp.107-112, 2011.

R. D. Zhang, J. E. Price, G. Schackert, K. Itoh, and I. J. Fidler, Malignant potential of cells isolated from lymph node or brain metastases of melanoma patients and implications for prognosis, Cancer Res, vol.51, pp.2029-2035, 1991.

J. Gachet, J. Giroux, and V. Girre, Métastases cérébrales dans les cancers du sein. Épidémiologie et histoire naturelle. Expérience de l'Institut Curie à travers deux études : les patientes HER2-de moins de 65 ans et les patientes de plus de 65 ans, Bull Cancer, vol.98, pp.357-69, 2011.

F. Casteillo, J. Guy, P. Dal-col, G. Karpathiou, B. Pommier et al., Pathologic Subtypes of Lung Adenocarcinoma Brain Metastasis is a Strong Predictor of Survival After Resection, The American Journal of Surgical Pathology, p.1, 2018.

N. Rekhtman, D. C. Ang, and G. J. Riely, KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma, Mod Pathol, vol.26, pp.1307-1319, 2013.

S. Wang, T. An, J. Wang, J. Zhao, Z. Wang et al., Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.16, issue.4, pp.1324-1330, 2010.

Y. Loriot, P. Mordant, E. Deutsch, K. A. Olaussen, and J. C. Soria, Are RAS mutations predictive markers of resistance to standard chemotherapy?, Nat Rev Clin Oncol, vol.6, pp.528-562, 2009.

T. Winton, R. Livingston, and D. Johnson, Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer, N Engl J Med, vol.352, pp.2589-97, 2005.

G. J. Riely and M. Ladanyi, KRAS mutations: an old oncogene becomes a new predictive biomarker, J Mol Diagn, vol.10, pp.493-498, 2008.

E. Kempf, B. Rousseau, B. Besse, and L. Paz-ares, KRASoncogene in lung cancer: focus on molecularly driven clinical trials, European Respiratory Review, vol.25, issue.139, pp.71-76, 2016.

M. A. Collins, F. Bednar, Y. Zhang, J. C. Brisset, S. Galban et al., Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice, J Clin Invest, vol.122, pp.639-653, 2012.

T. Li, Y. Zheng, H. Sun, R. Zhuang, J. Liu et al., K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis, Med Oncol, vol.33, p.61, 2016.

R. Zhuang, S. Li, Q. Li, X. Guo, F. Shen et al., The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis, PLOS ONE, vol.12, issue.8, p.182562, 2017.

B. M. Alexander, P. D. Brown, and P. Y. Wen, Response Assessment in Neuro-Oncology (RANO) group. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group Lancet Oncol, vol.19, pp.33-42, 2018.

K. Fizazi and G. Pentheroudakis, on behalf of the ESMO Guidelines Committee; Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.26, pp.133-138, 2015.

L. Ding, G. Getz, and D. A. Wheeler, Somatic mutations affect key pathways in lung adenocarcinoma, Nature, vol.455, pp.1069-75, 2008.

S. Billah, J. Stewart, and G. Staerkel, EGFR and KRAS mutations in lung carcinoma : Molecular testing by using cytology specimens, Cancer Cytopathol, vol.119, pp.111-118, 2011.

G. Klein, Foulds' dangerous idea revisited: the multistep development of tumors 40 years later, Adv Cancer Res, vol.72, pp.1-23, 1998.

C. A. Klein, Parallel progression of primary tumours and metastasis, Nat Rev Cancer, vol.9, pp.302-314, 2009.

P. K. Brastianos, S. L. Carter, and S. Santagata, Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets, Cancer Discov, vol.5, pp.1164-77, 2015.

E. Richtig, ASCO Congress 2018: melanoma treatment. Memo -Magazine of, European Medical Oncology, vol.11, issue.4, pp.261-265, 2018.

. Serment-d'hippocrate,

, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux. Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer

, Admise dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses

B. Charlotte and . Serment-d'hippocrate,

, En présence des Maîtres de cette FACULTE et de mes chers CONDISCIPLES, je promets et je jure d'être fidèle aux lois de l'Honneur et de la Probité dans l

, Je donnerai mes soins gratuits à l'indigent et je n'exigerai jamais un salaire au-dessus de mon travail

, Admis dans l'intérieur des maisons, mes yeux ne verront pas ce qui s'y passe, ma langue taira les secrets qui me seront confiés et mon état ne servira pas à corrompre les moeurs ni à favoriser le crime

, Respectueux et reconnaissant envers mes MAÎTRES, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères

, Que les HOMMES m'accordent leur estime si je suis fidèle à mes promesses. Que je sois couvert d'OPPROBRE et méprisé de mes confrères si j'y manque

B. Charlotte,